Technical Analysis for AERI - Aerie Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
42.15 | -1.56% | -0.67 |
AERI closed down 1.56 percent on Wednesday, January 16, 2019, on 89 percent of normal volume. It was able to find support at its 50 day moving average. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Up | Up |
| See historical AERI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 16 | 50 DMA Support | Bullish | 0.00% |
| Jan 16 | Outside Day | Range Expansion | 0.00% |
| Jan 16 | Wide Bands | Range Expansion | 0.00% |
| Jan 16 | Overbought Stochastic | Strength | 0.00% |
| Jan 15 | NR7 | Range Contraction | -1.56% |
| Jan 15 | Wide Bands | Range Expansion | -1.56% |
| Jan 15 | Overbought Stochastic | Strength | -1.56% |
| Jan 14 | MACD Bullish Centerline Cross | Bullish | -0.35% |
| Jan 14 | Upper Bollinger Band Walk | Strength | -0.35% |
| Jan 14 | Wide Bands | Range Expansion | -0.35% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-06
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its product candidates include dual-action AR-13324, a once-daily eye drop to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension, which has completed a Phase IIb clinical trials; triple-action PG324, a single drop fixed-dose combination of AR-13324 and latanoprost for the treatment of patients with glaucoma; and AR-13533, a dual-action ROCK/NET inhibitor that is in preclinical development stage. The company was founded in 2005 and is headquartered in Bedminster, New Jersey.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more AERI news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 74.75 |
| 52 Week Low | 32.18 |
| Average Volume | 608,894 |
| 200-Day Moving Average | 54.8871 |
| 50-Day Moving Average | 41.065 |
| 20-Day Moving Average | 37.8125 |
| 10-Day Moving Average | 40.63 |
| Average True Range | 2.141 |
| ADX | 27.92 |
| +DI | 24.4362 |
| -DI | 19.2112 |
| Chandelier Exit (Long, 3 ATRs ) | 37.127 |
| Chandelier Exit (Short, 3 ATRs ) | 38.603 |
| Upper Bollinger Band | 44.3375 |
| Lower Bollinger Band | 31.2875 |
| Percent B (%b) | 0.83 |
| BandWidth | 34.512397 |
| MACD Line | 0.5237 |
| MACD Signal Line | -0.4769 |
| MACD Histogram | 1.0006 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.53 Billion |
| Num Shares | 36.3 Million |
| EPS | -3.26 |
| Price-to-Earnings (P/E) Ratio | -12.93 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 12.18 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 46.22 | ||||
| Resistance 3 (R3) | 46.23 | 44.89 | 45.54 | ||
| Resistance 2 (R2) | 44.89 | 43.85 | 44.88 | 45.31 | |
| Resistance 1 (R1) | 43.52 | 43.22 | 42.85 | 43.51 | 45.09 |
| Pivot Point | 42.18 | 42.18 | 41.85 | 42.17 | 42.18 |
| Support 1 (S1) | 40.81 | 41.14 | 40.14 | 40.80 | 39.21 |
| Support 2 (S2) | 39.47 | 40.51 | 39.46 | 38.99 | |
| Support 3 (S3) | 38.10 | 39.47 | 38.76 | ||
| Support 4 (S4) | 38.09 |
